🔗 Permalink

Inventor profile of:

Daniel VITT

City:

Germering

Country:

Germany

Published Applications:

Last publication date:

2026-05-14

Top Assignees for applications by Daniel VITT

The entities that hold a legal rights for patent applications filed by inventor VITT Daniel:

Immunic AG 10 Gräfelfing, Germany
Immunic AG 2 Planegg-Martinsried, Germany
4SC AG 2 Martinsried, Germany
4SC AG 2 Planegg-Martinsried, Germany
4 SC AG 2 Planegg-Martinsried, Germany
4SC DISCOVERY GMBH 1 Planegg-Martinsried, Germany
4SC MG 1 Planegg-Martinsried, Germany

Recent patent applications by VITT Daniel

Daniel VITT from Germering, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-14

US20260130879A1

Human necessities

VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS

#2 | 2025-07-31

US20250243190A1

Chemistry; metallurgy

NEW DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS

#3 | 2025-05-01

US20250136542A1

Chemistry; metallurgy

CALCIUM SALT POLYMORPHS AS ANTI-INFLAMMATORY, IMMUNODULATORY AND ANTI-PROLIFERATIVE AGENTS

#4 | 2025-04-17

US20250120931A1

Human necessities

TREATMENT OF MULTIPLE SCHLEROSIS COMPRISING DHODH INHIBITORS

#5 | 2025-02-27

US20250066290A1

Chemistry; metallurgy

DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE

#6 | 2025-01-30

US20250032527A1

Human necessities

MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS

#7 | 2024-11-07

US20240368145A1

Chemistry; metallurgy

METHODS FOR TREATING CANCER

#8 | 2024-10-10

US20240335405A1

Human necessities

VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS

#9 | 2024-06-20

US20240199535A1

Chemistry; metallurgy

DEUTERATED DHODH INHIBITORS

#10 | 2024-06-06

US20240180858A1

Human necessities

Treatment of Multiple Sclerosis Comprising DHODH Inhibitors

#11 | 2024-03-28

US20240100005A1

Human necessities

Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases

#12 | 2023-04-13

US20230116729A1

Human necessities

Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases

#13 | 2023-02-16

US20230051911A1

Human necessities

Treatment of multiple sclerosis comprising DHODH inhibitors

#14 | 2022-10-27

US20220339132A1

Human necessities

Vidofludimus for use in the treatment or prevention of viral diseases

#15 | 2021-10-21

US20210322351A1

Human necessities

Vidofludimus for use in the treatment or prevention of viral diseases

#16 | 2021-03-04

US20210061796A1

Chemistry; metallurgy

IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation

#17 | 2021-01-21

US20210017125A1

Chemistry; metallurgy

Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents

#18 | 2020-11-19

US20200360324A1

Human necessities

Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases

#19 | 2018-07-19

US20180201606A1

Chemistry; metallurgy

Method of inhibiting DYRK1B

#20 | 2014-12-18

US20140371251A1

Chemistry; metallurgy

Method of inhibiting DYRK1B

#21 | 2012-02-09

US20120035175A1

Chemistry; metallurgy

Novel salts as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents

#22 | 2012-02-02

US20120029034A1

Chemistry; metallurgy

Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents

#23 | 2010-11-04

US20100280081A1

Human necessities

Anti-inflammatory agents as virostatic compounds

#24 | 2008-10-09

US20080249114A1

Chemistry; metallurgy

Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments

InventorID:

1007600 ⎘